Endpoint
Melanoma incidence
CAT:outcome/melanoma-incidencereported in proportion1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| nicotinamide | no effect | 1 | Evidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding. |
Every finding here is a null result.
Measured, no effect detected
1 finding
nicotinamide — no detected effect on
StrongEvidence strength: strong. Randomised human trials or their synthesis, with the effect's size and interval recorded and no recorded weakness outstanding.FindingNull result“No difference in risk of melanoma was observed with nicotinamide compared to control (RR 0.89 (95% CI, 0.29-2.79; I 2 = 0%; 416 patients; 2 trials)).”
Quoted verbatim from Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 416
- Population
- Pooled randomised trials of nicotinamide versus control, mainly tertiary skin-cancer prevention populations (2 trials)
Effect 0.89 risk ratio, 95% CI 0.29 to 2.79
Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.2022PMID:35134311Permalink
How it is measured
Incident cutaneous melanoma diagnoses ascertained by cancer registry linkage, pathology report, or medical record review.
Sources cited
1 paper
- Subject
- melanoma incidence
- Findings
- 1
- Papers
- 1